Brief: Bioporto Says Receives FDA 510(K) Clearance For NGAL Test In United States First Test To Aid In Assessing AKI Risk For Patients Aged 3 Months Through 21 Years

BioPorto A/S

07/12/2023 21:25

Dec 7 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * BIOPORTO RECEIVES FDA 510(K) CLEARANCE FOR NGAL TEST IN
UNITED
STATES FIRST TEST TO AID IN ASSESSING AKI RISK FOR PATIENTS AGED
3 MONTHS THROUGH 21 YEARS
    * BIOPORTO A/S - EXPECTS THAT US SALES THROUGH ITS
DISTRIBUTION
AGREEMENT WITH ROCHE DIAGNOSTICS GMBH (ROCHE) WILL BEGIN IN
SECOND HALF OF 2024
    * BIOPORTO A/S- ANNOUNCEMENT DOES NOT ALTER BIOPORTO'S
FINANCIAL
GUIDANCE FOR 2023

Source text for Eikon:  ID:nGNE38WJ61 
Further company coverage:  BIOPOR.CO 

 ((Reuters.Briefs@thomsonreuters.com;))